In controlled clinical studies involving approximately 1,400 patients, the following adverse reactions have been reported in patients treated with colesevelam. When reporting to the very common (≥ 1 / 10), common (≥ 1 / 100, 51/10), uncommon (≥ 1 / 1000, 51/100), rare (≥ 1/10.000, 51/1000) and distinction very rarely (51/10.000), including individual cases:

 
*Investigations Common: serum triglyceride increased; Uncommon: serum transaminase increases

 
*Nervous system disorders Common: headache

 
*Gastrointestinal disorders Very Common: flatulence, constipation; Common: vomiting, diarrhea, dyspepsia, abdominal pain, stool abnormalities, nausea

 
*Musculoskeletal and connective tissue disorders Uncommon: myalgia

 
The background incidence of flatulence and diarrhea was in patients in the same controlled clinical trials, the placebo were higher. Only constipation and dyspepsia were shown to occur in a higher percentage of patients who received Cholestagel, compared to the placebo reported. Side effects were generally mild or moderate in severity.  In the application of colesevelam in combination with statins, no unexpected frequent side effects occurred.<ref name="fi">[http://www.genzyme.de/prod/pdf-prod/de_pdf_pt_chol_fachinfo.pdf Consumer information for cholestagel] {{webarchive|url=https://web.archive.org/web/20110719031609/http://www.genzyme.de/prod/pdf-prod/de_pdf_pt_chol_fachinfo.pdf |date=2011-07-19 }}, March 2009 {{de icon}}</ref>

 

